Noam VanderWalde1, Jennifer Moughan2, Stuart M Lichtman3, Reshma Jagsi4, Matthew Ballo5, Ari VanderWalde5, Mohammed Mohiuddin6, Neal J Meropol7, Lisa Kachnic8, Adam Berger9, Jaffer Ajani10, Rani Anne11, Judith L Hopkins12, Amit Arora13, Joshua Meyer14, Susannah G Ellsworth15, R Jeffrey Lee16, Nathan Green17, Christopher H Crane3. 1. University of Tennessee Health Science Center/The West Clinic - Wolf River, USA. Electronic address: nvanderw@westclinic.com. 2. NRG Oncology Statistics and Data Management Center, USA. 3. Memorial Sloan Kettering Cancer Center, USA. 4. University of Michigan, USA. 5. University of Tennessee Health Science Center/The West Clinic - Wolf River, USA. 6. University of Kentucky, USA. 7. Flatiron Health/Case Comprehensive Cancer Center, Case Western Reserve University, USA. 8. Columbia University, Herbert Irving Comprehensive Cancer Center, USA. 9. Rutgers Cancer Institute of New Jersey, USA. 10. MD Anderson Cancer Center, USA. 11. Thomas Jefferson University, USA. 12. Novant Health Oncology Specialists, USA. 13. Kaiser Permanente, USA. 14. Fox Chase Cancer Center, USA. 15. University of Pittsburgh Medical Center, USA. 16. Intermountain Medical Center, USA. 17. Southeast Nebraska Cancer Care, USA.
Abstract
PURPOSE: Expected toxicity from chemoradiation (CRT) is an important factor in treatment decisions but is poorly understood in older adults with lower gastrointestinal (GI) malignancies. Our objective was to compare acute adverse events (AAEs) of older and younger adults with lower GI malignancies treated on NRG studies. METHODS: Data from 6 NRG trials, testing combined modality therapy in patients with anal or rectal cancer, were used to test the hypothesis that older age was associated with increased AAEs. AAEs and compliance with protocol-directed therapy were compared between patients aged ≥70 and < 70. Categorical variables were compared across age groups using the chi-square test. The association of age on AAEs was evaluated using a covariate-adjusted logistic regression model, with odds ratio (OR) reported. To adjust for multiple comparisons, a p-value <0.01 was considered statistically significant. RESULTS: There were 2525 patients, including 380 patients ≥70 years old (15%) evaluable. Older patients were more likely to have worse baseline performance status (PS 1 or 2) (23% vs. 16%, p = 0.001), but otherwise baseline characteristics were similar. Older patients were less likely to complete their chemotherapy (78% vs. 87%, p < 0.001), but had similar RT duration. On univariate analysis, older patients were more likely to experience grade ≥ 3 GI AAEs (36% vs. 23%, p < 0.001), and less likely to experience grade ≥ 3 skin AAEs (8% vs. 14%, p = 0.002). On multivariable analysis, older age was associated with grade ≥ 3 GI AAE (OR 1.93, 95% CI: 1.52, 2.47, p < 0.001) after adjusting for sex, race, PS, and disease site. CONCLUSIONS: Older patients with lower GI cancers who underwent CRT were less likely to complete chemotherapy and had higher rates of grade 3+ GI AAEs. These results can be used to counsel older adults prior to treatment and manage expected toxicities throughout pelvic CRT.
PURPOSE: Expected toxicity from chemoradiation (CRT) is an important factor in treatment decisions but is poorly understood in older adults with lower gastrointestinal (GI) malignancies. Our objective was to compare acute adverse events (AAEs) of older and younger adults with lower GI malignancies treated on NRG studies. METHODS: Data from 6 NRG trials, testing combined modality therapy in patients with anal or rectal cancer, were used to test the hypothesis that older age was associated with increased AAEs. AAEs and compliance with protocol-directed therapy were compared between patients aged ≥70 and < 70. Categorical variables were compared across age groups using the chi-square test. The association of age on AAEs was evaluated using a covariate-adjusted logistic regression model, with odds ratio (OR) reported. To adjust for multiple comparisons, a p-value <0.01 was considered statistically significant. RESULTS: There were 2525 patients, including 380 patients ≥70 years old (15%) evaluable. Older patients were more likely to have worse baseline performance status (PS 1 or 2) (23% vs. 16%, p = 0.001), but otherwise baseline characteristics were similar. Older patients were less likely to complete their chemotherapy (78% vs. 87%, p < 0.001), but had similar RT duration. On univariate analysis, older patients were more likely to experience grade ≥ 3 GI AAEs (36% vs. 23%, p < 0.001), and less likely to experience grade ≥ 3 skin AAEs (8% vs. 14%, p = 0.002). On multivariable analysis, older age was associated with grade ≥ 3 GI AAE (OR 1.93, 95% CI: 1.52, 2.47, p < 0.001) after adjusting for sex, race, PS, and disease site. CONCLUSIONS: Older patients with lower GI cancers who underwent CRT were less likely to complete chemotherapy and had higher rates of grade 3+ GI AAEs. These results can be used to counsel older adults prior to treatment and manage expected toxicities throughout pelvic CRT.
Authors: Brian D Kavanagh; Charlie C Pan; Laura A Dawson; Shiva K Das; X Allen Li; Randall K Ten Haken; Moyed Miften Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Marcus Foo; Emma Link; Trevor Leong; Julie Chu; Mark T Lee; Sarat Chander; Phillip K Tran; Jonathan M Tomaszewski; Michael Michael; Alexander Heriot; Samuel Y Ngan Journal: Acta Oncol Date: 2014-01-23 Impact factor: 4.089
Authors: T Pignon; J C Horiot; M Bolla; H van Poppel; H Bartelink; F Roelofsen; F Pene; A Gerard; N Einhorn; T D Nguyen; M Vanglabbeke; P Scalliet Journal: Radiother Oncol Date: 1997-02 Impact factor: 6.280
Authors: Leonard L Gunderson; Kathryn A Winter; Jaffer A Ajani; John E Pedersen; Jennifer Moughan; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher G Willett Journal: J Clin Oncol Date: 2012-11-13 Impact factor: 44.544
Authors: M Flam; M John; T F Pajak; N Petrelli; R Myerson; S Doggett; J Quivey; M Rotman; H Kerman; L Coia; K Murray Journal: J Clin Oncol Date: 1996-09 Impact factor: 44.544